title: Lack of effect of ustekinumab in treatment of allergic contact dermatitis.
abstract: BACKGROUND
  Allergic contact dermatitis is a chronic inflammatory T cell mediated disease that can be recalcitrant to existing treatments. Ustekinumab is a monocloncal antibody blocking IL-12 and IL-23, shown to be effective and safe for patients with psoriasis. Despite both IL-12 and IL-23 involvement in contact allergy, the effect of Ustekinumab on allergic contact dermatitis has not been reported.
  
  
  OBJECTIVE
  To evaluate the clinical effect of Ustekinumab in patients with allergic contact dermatitis.
  
  
  METHODS
  A retrospective, case cohort study of patients with allergic contact dermatitis treated with Ustekinumab in our department.
  
  
  RESULTS
  Five patients had been treated with Ustekinumab for allergic contact dermatitis, with limited effect.
  
  
  CONCLUSIONS
  Our observation suggests that, although theoretically plausible, Ustekinumab does not seem to be a valuable therapeutic approach for chronic allergic contact dermatitis.
authors: Department of Dermato-Allergology, University Hospital of Copenhagen, 2900 Hellerup, Denmark. Nanban01@geh.regionh.dk
authors: Nannie
authors: N
authors: Bangsgaard
authors: Claus
authors: C
authors: Zachariae
authors: Torkil
authors: T
authors: Menné
authors: Lone
authors: L
authors: Skov
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D017449:Dermatitis, Allergic Contact / Q000188:drug therapy*; D003879:Dermatologic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D017211:Treatment Failure; D000069549:Ustekinumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D003879:Dermatologic Agents; D000069549:Ustekinumab